Favourer slide of #ASCO2022 Matt Milowski showing pCR rates for chemo vs IO vs chemo/IO in MIBC. They all look the same. Is single agent pembro really as good as ddMVAV? is comparing different regimens fair? Is this a useful endpoint? What does it mean for the IO/chemo trials?
Should I order a PET scan? Integrating molecular imaging into urologic oncology clinical practice: Current approaches and future opportunities
@MABjurlin@TracyLRoseMD@thomashopemd@michael_gorin#AUA22 Room 207, Course 002IC 730-930am
Thrilled our study of chemo-immunotherapy in MIBC was published in JCO this week! My @ASCO@AACR#Vail workshop protocol and a great collaboration between @UNC_Lineberger and @DukeGUCancer - thanks to all for the tremendous support along the way, most especially @MattMilowsky
The two week countdown begins! 🔊 It's easier than ever to get involved in this year’s virtual Walk to End Bladder Cancer. Whether you're joining a team or walking as an individual, your participation makes a difference. Join us on Saturday, May 1: https://t.co/0ql5kuixHw
Do you love #walks? Why not walk and raise money and awareness for #bladdercancer? You can walk anytime and anywhere on May 1, 2021 and then join us for an awesome virtual event! Register today at https://t.co/a0tEoOMpA5! @MaryWDunn@TracyLRoseMD